Sanofi plans to restructure its organizational structure and establish five global business units

Source: 2015-7-20 Sanofi plans to restructure its global business and establish five global business units: General Medicine & emerging markets, specialty nursing, diabetes & cardiovascular, Senauer Faye Basudeb and Meria The new organizational structure will be implemented from January 2016 Sanofi is inherited from several companies with more than 100 years of experience in the pharmaceutical industry This heritage has enabled Sanofi to export highly innovative therapeutic drugs to meet the changing needs of patients, medical providers and customers Sanofi will probably launch six new drugs in 2015, and there will be about one new drug on the market every six months from 2016 to 2018, and Sanofi is currently preparing to achieve substantial growth Guter, Meeker and Witz were appointed to lead the new Sanofi global business unit "with a streamlined new organizational structure that will focus Sanofi on advantage growth," said brandicourt, CEO "This restructuring is a necessary step to ensure that Sanofi's new drugs and vaccines continue to build our tradition of providing innovative healthcare treatments "The global business unit of General Medicine & emerging markets will be led by Guenter, which will be composed of Sanofi's old brand products, generics, consumer health and all pharmaceutical businesses in emerging markets The global business unit of specialized nursing is to be named Sanofi jianzan, which will be led by Meeker The unit will be composed of Sanofi's rare disease drugs, multiple sclerosis, tumor and immune drugs, including two experimental biological drugs sarilumab and dupilumab The Diabetes & Cardiovascular global business unit will be led by Witz, which will consist of Sanofi's diabetes drugs and cardiovascular drugs, including praluent (alirocumab), which is currently under review by FDA and EMA Sanofi Pasteur and Meria are two global business units that will continue to manage their current vaccine products and animal health products Charmeil will continue to lead Sanofi Pasteur, while Hellmann will continue to lead Merial Similar to the R & D and Industry Affairs model, all functions will be globalized to better serve the business unit.